Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Size in the 7MM is expected to grow a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CIDP, historical and forecasted epidemiology, as well as the CIDP market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover which therapies are expected to grab the Chronic Inflammatory Demyelinating Polyneuropathy Market Share @ Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report
• In March 2025:- Dianthus Therapeutics conducted a study of phase 3 is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
• In March 2025:- Sanofi announced a study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
• In March 2025:- Octapharma, multicenter, prospective, double-blinded, parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients.
• In 2023, the US accounted for the highest diagnosed prevalent cases of CIDP with approximately 30,230 cases, which are expected to increase by 2034.
• Among EU4 and the UK, the UK had the highest diagnosed prevalent cases of CIDP, with nearly 3,250 cases in 2023, followed by Germany with around 3,174 cases. In contrast, Spain has the lowest number, with nearly 1,691 cases.
• In 2023, Japan accounted for approximately 2,045 diagnosed prevalent cases of CIDP which are expected to increase by 2034.
• In 2023, among the subtype-specific cases of CIDP, the US accounted for approximately 15,417 cases for typical CIDP and 14,813 cases for atypical CIDP.
• In 2023, Germany had approximately 2,380 males and 793 females diagnosed with CIDP.
• In 2023, the diagnosed prevalent cases of CIDP across the age groups 0-19 years, 20-39 years, 40-59 years, 60-79 years and 80 years and older were approximately 41, 82, 798, 900 and 225, respectively, in Japan.
• The leading Chronic Inflammatory Demyelinating Polyneuropathy Companies such as Takeda, Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Shire, Argenx, Sanofi, Nihon Pharmaceutical, Immunovant Sciences, Octapharma, CSL Behring, Janssen Research, Novartis, Biogen, UCB Biopharma, Takeda, MedDay Pharmaceuticals, Teijin Pharma, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, Bio Products Laboratory, Baxter, GeNeuro Pharmaceuticals, and others
• Promising Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapies such as HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc), GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution), Riliprubart (SAR445088), Nipocalimab, Batoclimab (HL161), Efgartigimod, SAR445088, NPB-01, Batoclimab, Panzyga, IgPro20, Nipocalimab, Fingolimod, Interferon Beta-1a, Rozanolixizumab, TAK-771, MD1003, and others.

Stay ahead in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market with DelveInsight's Strategic Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation in the 7MM
• Total Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy
• Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy by severity
• Gender-specific Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy
• Diagnosed Cases of Episodic and Chronic Chronic Inflammatory Demyelinating Polyneuropathy

Download the report to understand which factors are driving Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Prevalence- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Chronic Inflammatory Demyelinating Polyneuropathy Drugs

• HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda
HYQVIA is an immunostimulant combining human immunoglobulin (IG 10%) with recombinant human hyaluronidase, enabling SC for easier administration. This treatment offers a convenient alternative to IVIg by allowing larger-volume, less frequent SC due to enhanced absorption. HYQVIA modulates the immune system to reduce autoimmune damage to the nerves in CIDP. In January 2024, the US FDA approved HYQVIA for the maintenance treatment of CIDP in adults. The European Commission also approved it for the same purpose, and the UK's MHRA granted approval in March 2024. Takeda filed for approval in Japan in August 2024.

• VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx
VYVGART HYTRULO is a coformulation of efgartigimod alfa and recombinant human hyaluronidase, designed to enhance SC absorption. It works by reducing autoantibodies implicated in CIDP through inhibition of the FcRn receptor. Approved by the US FDA in June 2024, it received orphan drug designation for CIDP in 2021. This therapy offers a convenient option for maintaining remission via SC administration.

• GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda
GAMMAGARD LIQUID/KIOVIG is a ready-to-use IV formulation of IVIg derived from human plasma, offering a broad spectrum of antibodies. It works by modulating the immune system, reducing inflammation, and preventing further nerve damage in CIDP. Clinical studies have shown its effectiveness in improving muscle strength and functional ability, helping manage symptoms and maintain long-term stability. It was approved by the US FDA in January 2024 for adults with CIDP. In May 2019, KIOVIG was also approved in the EU for treating CIDP in adults, children, and adolescents (0-18 years).

Emerging Chronic Inflammatory Demyelinating Polyneuropathy Drugs
• Riliprubart (SAR445088): Sanofi
Riliprubart (SAR445088) is an investigational IgG4 humanized monoclonal antibody designed to block activated C1s, a key component of the classical complement pathway. By inhibiting C1s, it aims to reduce inflammation and prevent nerve damage in CIDP. Currently in Phase III, riliprubart targets CIDP patients resistant to standard treatments or IVIg. The FDA granted ODD in July 2021. Submission timelines for CIDP treatment are projected for completion by 2026.

• Nipocalimab: Janssen Research and Development
Nipocalimab (JNJ-80202135) is an investigational monoclonal antibody that acts as an FcRn inhibitor, administered IV. It targets harmful IgG antibodies, without broadly suppressing the immune system. It is in Phase II/III trials for CIDP. In October 2021, the US FDA granted ODD to nipocalimab for its potential use in treating CIDP. Additionally it is anticipated that the ongoing trials of nipocalimab could be pivotal in shaping its clinical potential in the realm of CIDP treatment.

• Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences
Batoclimab (HL161) is a fully human monoclonal antibody targeting FcRn, developed as a SC injection for autoimmune diseases driven by IgG antibodies, including CIDP. It works by inhibiting FcRn, promoting IgG breakdown and reducing its levels. Currently in Phase II trials for CIDP, top-line results are expected by March 2025. Batoclimab's data will guide the design of future trials and regulatory approval for CIDP therapies.

To learn more about Chronic Inflammatory Demyelinating Polyneuropathy treatment guidelines, visit @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Landscape- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Inflammatory Demyelinating Polyneuropathy Drugs Market Insights
Chronic inflammatory demyelinating polyneuropathy treatment primarily involves corticosteroids as the first-line therapy, often combined with immunosuppressants like methotrexate or azathioprine for patients who do not respond adequately. In cases of severe or resistant disease, IVIg may be beneficial, and biologics such as rituximab can be considered for some cases. Emerging therapies include riliprubart (SAR445088), nipocalimab (JNJ-80202135), and batoclimab (HL161).
• Riliprubart (SAR445088), is an investigational IgG4 humanized monoclonal antibody designed to selectively block activated C1s, a key component of the classical complement pathway in the innate immune system.
• Nipocalimab (JNJ-80202135) is an investigational, high-affinity monoclonal antibody administered IV as an FcRn inhibitor. It is currently in Phase II/III clinical trials for CIDP.
• Batoclimab (HL161) a subcutaneous anti-FcRn antibody. Batoclimab specifically inhibits FcRn, promoting the breakdown of IgG and reducing its levels in circulation. It is being developed collaboratively by Immunovant, with HanAll Biopharma leading efforts to expand its indications. It targets rare autoimmune diseases by reducing IgG levels.

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook
Chronic inflammatory demyelinating polyneuropathy, though classified as a rare disease, has gained increasing recognition in recent years. This is largely due to improvements in diagnostic techniques, greater awareness among healthcare professionals, and a deeper understanding of the condition. Management of CIDP typically involves a combination of pharmacological therapies and supportive interventions, with the primary objectives to suppress inflammation, modulate immune responses, and improve motor and sensory function.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
The Chronic Inflammatory Demyelinating Polyneuropathy treatment market landscape has advanced with a multi-faceted approach, combining medications, and supportive care. Corticosteroids, such as prednisone and dexamethasone, are often the initial treatment. While they are effective in inducing remission, they carry a high risk of significant long-term side effects, including osteoporosis, weight gain, and increased susceptibility to infections. These adverse effects often necessitate combination therapies with steroid-sparing agents, which may not be universally effective.

Learn more about the FDA-approved drugs for Chronic Inflammatory Demyelinating Polyneuropathy @ Drugs for Chronic Inflammatory Demyelinating Polyneuropathy Treatment- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Inflammatory Demyelinating Polyneuropathy Companies- Takeda, Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Shire, Argenx, Sanofi, Nihon Pharmaceutical, Immunovant Sciences, Octapharma, CSL Behring, Janssen Research, Novartis, Biogen, UCB Biopharma, Takeda, MedDay Pharmaceuticals, Teijin Pharma, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, Bio Products Laboratory, Baxter, GeNeuro Pharmaceuticals, and others
• Promising Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapies such as HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc), GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution), Riliprubart (SAR445088), Nipocalimab, Batoclimab (HL161), Efgartigimod, SAR445088, NPB-01, Batoclimab, Panzyga, IgPro20, Nipocalimab, Fingolimod, Interferon Beta-1a, Rozanolixizumab, TAK-771, MD1003, and others.
• Parkinson's Disease Psychosis Therapeutic Assessment: Parkinson's Disease Psychosis current marketed and Parkinson's Disease Psychosis emerging therapies
• Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: Chronic Inflammatory Demyelinating Polyneuropathy market drivers and Chronic Inflammatory Demyelinating Polyneuropathy market barriers
• Chronic Inflammatory Demyelinating Polyneuropathy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs, KOL's views, Analyst's views, Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement

Discover more about Chronic Inflammatory Demyelinating Polyneuropathy Drugs in development @ Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction
3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview at a Glance
4. Chronic Inflammatory Demyelinating Polyneuropathy Executive Summary
5. Key Events
6. Chronic Inflammatory Demyelinating Polyneuropathy Disease Background and Overview
7. Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Market Methodology
8. Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population
9. Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey
10. Chronic Inflammatory Demyelinating Polyneuropathy Marketed Therapies
11. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drug Profiles
12. Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis
13. Key Opinion Leaders' Views
14. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs
15. Chronic Inflammatory Demyelinating Polyneuropathy SWOT Analysis
16. Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.